Table 1

Baseline and treatment characteristics and comparison by subgroups

VariableTotal (n=112)Group 1 (n=47)Group 2 (n=65)P value
Days from symptom onset to tocilizumab administration11 (9–13)8 (7–10)13 (12–16)<0.001
Days from onset of symptoms to admission7 (6–10)6 (5–7)9 (7–10)<0.001
Days from admission to administration of tocilizumab3 (2–5)2 (1–3)5 (2–7)<0.001
Age, years58 (48–85)56 (45–67)60 (49–64)0.777
Men, n (%)83 (73.2)39 (83.0)43 (66.2)0.047
Race, n (%)
 Caucasian76 (67.9)31 (66.0)45 (69.2)0.714
 Latin31 (27.7)15 (31.9)16 (24.6)0.394
 Afro-American3 (2.7)1 (2.1)2 (3.1)0.759
 Asian2 (1.8)2 (3.1)0.225
Confirmed PCR for SARS-CoV-2, n (%)77 (68.8)34 (72.3)43 (66.1)0.586
Active smoker, n (%)4 (3.6)2 (4.3)2 (3.1)0.74
Presence of at least one comorbidity, n (%)51 (45.5)23 (48.9)28 (43.1)0.539
Comorbidities, n (%)
 HT72 (64.3)21 (44.7)19 (29.2)0.092
 DM22 (19.7)10 (21.3)12 (18.5)0.711
 COPD7 (6.3)3 (6.4)4 (6.2)1
 CVD6 (5.4)2 (4.3)4 (6.2)1
 ESRD5 (4.5)2 (4.3)3 (4.6)1
 Asthma4 (3.6)2 (4.3)2 (3.1)1
 Active cancer4 (3.6)4 (6.2)0.138
Corticosteroid treatment, n (%)76 (67.9)33 (70.2)43 (66.2)0.65
Use of pulsed corticosteroids, n (%)65 (58.0)29 (61.7)36 (55.4)0.504
Concomitant treatments, n (%)
 HCQ110 (98.2)46 (97.9)64 (98.5)1
 Ceftriaxone106 (94.6)43 (91.5)63 (96.9)0.236
 LPV/r106 (94.6)45 (95.7)61 (93.9)1
 Azithromycin105 (93.8)44 (93.6)61 (93.9)1
 β-interferon 1b8 (7.1)3 (6.4)5 (7.7)1
 Immunoglobulins3 (2.7)1 (2.1)2 (3.1)1
No of tocilizumab doses, n (%)
 178 (69.6)31 (66.0)47 (72.3)0.471
 231 (27.7)15 (31.9)16 (24.6)0.394
 33 (2.7)1 (2.1)2 (3.1)1
  • ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; ESRD, end-stage renal disease; HCQ, hydroxychloroquine; HT, hypertension; LPV/r, lopinavir/ritonavir; RI, renal insufficiency.